SELLAS Life Sciences Group, Inc. (SLS): who owns it and who trades it
As of Nov 16, 2026, SLS insiders reported 1 purchase worth $101K in the last 12 months. The largest buyer was Katherine Bach Kalin (Director), with $101K. 1 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling SELLAS Life Sciences Group
From the latest filingsOverall: more buying than selling. Insiders and famous investors mostly bought.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Insider trades
In the last 12 months, SLS insiders reported $101K of open-market purchases and $0 of sales.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Nov 19, 2025 | Katherine Bach Kalin | Director | Purchase | 63,400 | $1.59 | $101K | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Katherine Bach Kalin | Director | $101K | – | Nov 19, 2025 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
SLS short interest
Very high short interest. 28.3% of SLS shares are sold short: about 1 share in 4. Over the last 12 reports the number of shares short barely changed.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 57.13M SLS shares were sold short, 28.3% of the shares outstanding, up 6.3% from the report before. At the average daily volume of 8.53M shares, buying them all back would take about 6.7 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 57.13M | 28.29% | +6% | 8.53M | 6.7 |
| Oct 15, 2026 | 53.76M | 26.62% | -2% | 4.50M | 11.9 |
| Sep 30, 2026 | 55.13M | 27.30% | -7% | 5.84M | 9.4 |
| Sep 15, 2026 | 59.07M | 29.25% | +2% | 6.87M | 8.6 |
| Aug 31, 2026 | 57.93M | 28.68% | +3% | 8.42M | 6.9 |
| Aug 14, 2026 | 56.37M | 27.91% | +3% | 5.40M | 10.4 |
| Jul 31, 2026 | 54.98M | 30.61% | -1% | 6.97M | 7.9 |
| Jul 15, 2026 | 55.28M | 30.78% | -13% | 9.33M | 5.9 |
| Jun 30, 2026 | 63.31M | 35.25% | -0% | 13.33M | 4.8 |
| Jun 15, 2026 | 63.36M | 35.28% | +4% | 6.85M | 9.2 |
| May 29, 2026 | 61.00M | 33.97% | +7% | 13.79M | 4.4 |
| May 15, 2026 | 57.07M | 31.78% | -0% | 7.99M | 7.1 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
SELLAS Life Sciences Group company events
SELLAS Life Sciences Group filed 9 reports on Form 8-K in the last 12 months, 1 of them about an important change (leadership). The latest was on Aug 11, 2026.
- Aug 11, 2026ResultsReleased financial results. Filing
- Jul 27, 2026AnnouncementAs previously disclosed, the Company commenced a binding arbitration against 3D Medicines, Inc., administered by the Hong Kong International Arbitration Centre. Filing
- Jun 25, 2026LeadershipSELLAS Life Sciences Group, Inc. entered into (i) an amendment to that certain employment agreement effective as of July 1, 2019, by and between the Company and Dr. Angelos Stergiou, the Company’s President and Chief Executive Officer, (ii) an amended and restated severance and change of control… Filing
- Jun 18, 2026VoteReported shareholder vote results. Filing
- Jun 2, 2026AnnouncementAs previously reported, as of March 31, 2026, SELLAS Life Sciences Group, Inc. had $107.1 million of cash and cash equivalents. Filing
- May 12, 2026ResultsReleased financial results. Filing
- Mar 19, 2026ResultsReleased financial results. Filing
- Mar 11, 2026AnnouncementAs previously reported on January 8, 2026, SELLAS Life Sciences Group, Inc. received approximately $26.5 million in proceeds as of such date from the exercise of common stock warrants subsequent to December 31, 2025. Filing
- Jan 8, 2026AnnouncementSubsequent to December 31, 2025, the Company received approximately $26.5 million in proceeds from the exercise of common stock warrants. Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
SELLAS Life Sciences Group financials
Famous investors that hold SLS
1 of the 50 well-known investors we track reported holding SLS in their latest 13F filing. The largest position is Paul Tudor Jones's, worth $2M.
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Paul Tudor Jones · Tudor Investment Corp | Q3 2026 | 162,687 | $2M | 0.0% | New |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
5%+ stakes filed in the last 120 days
Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 4 filings named SLS in the last 120 days.
| Filed | Holder | Form | Stake |
|---|---|---|---|
| Nov 10, 2026 | STATE STREET CORPORATION | 13G | 5.1% |
| Nov 10, 2026 | STATE STREET CORPORATION | 13G | 5.1% |
| Oct 27, 2026 | BlackRock, Inc. | 13G/A | 7.9% |
| Oct 27, 2026 | BlackRock, Inc. | 13G/A | 7.9% |
Questions about SELLAS Life Sciences Group, Inc. (SLS) stock
Are SLS insiders buying or selling?
In the last 12 months, SLS insiders reported 1 open-market purchase worth $101K and no sales. The latest trade was on Nov 19, 2025. See every trade.
What is the short interest in SLS?
As of Oct 30, 2026, 57.13M SLS shares were sold short, 28.3% of the shares outstanding, up 6.3% from the report before. At the average daily volume of 8.53M shares, buying them all back would take about 6.7 trading days (days to cover). See the history.
Which famous investors hold SLS?
1 of the 50 well-known investors we track reported SLS in their latest 13F filing, including Paul Tudor Jones. The largest position is worth $2M. See all holders.
Executive pay
SELLAS Life Sciences Group's chief executive was paid a total of $1.9M for the year ended Dec 31, 2025, up 58% from $1.2M the year before. In the last 12 months, SELLAS Life Sciences Group's executives and directors bought $101K of stock on the open market and sold none.
From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.